X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/eu-approves-sanofis-dupixent-smokers-lungs-2024-07-03/
https://www.globenewswire.com/news-release/2024/06/26/2904848/0/en/Dupixent-dupilumab-Positive-Phase-3-Data-in-Children-1-to-11-Years-of-Age-with-Eosinophilic-Esophagitis-Published-in-the-New-England-Journal-of-Medicine.html
https://www.globenewswire.com/news-release/2024/05/31/2891263/0/en/Press-Release-Dupixent-recommended-for-EU-approval-by-the-CHMP-to-treat-patients-with-COPD.html
https://www.globenewswire.com/news-release/2024/05/31/2891259/0/en/Press-Release-Update-on-FDA-priority-review-of-Dupixent-for-the-treatment-of-COPD-patients-with-type-2-inflammation.html
https://www.biopharmadive.com/news/johnson-johnson-numab-yellow-jersey-bispecific-atopic-dermatitis-eczema/717179/
https://www.globenewswire.com/news-release/2024/05/20/2885069/0/en/Dupixent-dupilumab-Late-Breaking-Data-from-NOTUS-Confirmatory-Phase-3-COPD-Trial-Presented-at-ATS-and-Published-in-The-New-England-Journal-of-Medicine.html
https://www.globenewswire.com/news-release/2024/05/13/2880075/0/en/Dupixent-dupilumab-sBLA-Accepted-for-FDA-Priority-Review-for-Treatment-of-Adolescents-with-Chronic-Rhinosinusitis-with-Nasal-Polyposis-CRSwNP.html
https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-priority-review-0
https://www.globenewswire.com/news-release/2024/05/07/2876615/0/en/ASLAN-Pharmaceuticals-to-Present-Additional-Data-From-Interim-Analysis-of-TREK-DX-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients-During-Virtual-KO.html
https://www.fiercepharma.com/pharma/regeneron-reports-potential-delay-dupixent-copd-stagnant-sales-eylea
https://www.globenewswire.com/news-release/2024/04/30/2872039/0/en/ASLAN-Pharmaceuticals-to-Host-KOL-Panel-Discussion-on-Treatment-Options-for-Atopic-Dermatitis-Patients-With-an-Inadequate-Response-to-Dupilumab.html
https://www.fiercepharma.com/marketing/regeneron-sanofi-du-more-dupixent-asthma-ads-using-humor-convey-breathe-better-message
https://www.sanofi.com/en/media-room/press-releases/2024/2024-04-26-05-00-00-2870215
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-q1-profit-slips-generic-competition-forex-effects-2024-04-25/
https://www.globenewswire.com/news-release/2024/04/22/2866887/0/en/ASLAN-Pharmaceuticals-Announces-Positive-Interim-Results-From-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sanofi-plans-to-launch-1-or-2-products-in-india-every-year/articleshow/108953999.cms
https://www.globenewswire.com//news-release/2024/02/23/2834220/0/en/Dupixent-dupilumab-sBLA-Accepted-for-FDA-Priority-Review-for-Treatment-of-COPD-with-Type-2-Inflammation.html
https://endpts.com/fda-sets-copd-approval-decision-date-for-sanofi-and-regenerons-dupixent-in-june/
https://www.fiercepharma.com/pharma/japan-green-lights-sanofi-and-regenerons-dupixent-hives-condition-following-fda-rejection
https://www.sanofi.com/en/media-room/press-releases/2024/2024-02-16-06-00-00-2830509
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-dupixent-treat-younger-kids-with-esophageal-condition-2024-01-25/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://www.globenewswire.com//news-release/2024/01/16/2809695/0/en/Dupixent-dupilumab-U-S-Label-Updated-with-Data-Further-Supporting-Use-in-Atopic-Dermatitis-with-Moderate-to-Severe-Hand-and-Foot-Involvement.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://endpts.com/kymera-doubles-down-on-protein-degraders-for-immunology-chasing-dupixent-and-sotyktu/
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-focus-12-blockbuster-drug-candidates-immunology-pipeline-2023-12-07/
https://www.fiercepharma.com/pharma/sanofi-and-regenerons-dupixent-scores-again-second-copd-trial
https://endpts.com/regeneron-expects-key-dupixent-copd-data-this-year-amid-eyleas-sales-decline-in-the-us/
https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-22-19-00-00-2764338
https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252
https://www.globenewswire.com//news-release/2023/09/26/2749151/0/en/Press-Release-Dupixent-dupilumab-sBLA-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1-to-11-accepted-for-FDA-Priority-Review.html
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-lifts-earnings-outlook-dupixent-sales-new-drug-launches-2023-07-28/
https://www.prnewswire.com/news-releases/20-of-dupixent-treated-atopic-dermatitis-patients-are-refractory-to-the-drug-marketvue-report-301886427.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055
https://www.indianpharmapost.com/news/dupixent-is-now-approved-in-india-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis-14387
https://www.fiercepharma.com/pharma/dupixent-leading-way-copd-sanofi-set-play-big-boys-and-girls-respiratory-diseases
https://www.globenewswire.com/news-release/2023/05/21/2672905/0/en/Dupixent-dupilumab-Late-breaking-Phase-3-COPD-Results-Presented-at-ATS-and-Simultaneously-Published-in-the-New-England-Journal-of-Medicine.html
https://www.sanofi.com/en/media-room/press-releases/2023/2023-05-08-12-30-00-2663289
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-23-06-00-00-2632822
https://www.nasdaq.com/articles/sanofis-sny-dupixent-gets-eu-nod-for-eczema-in-young-kids
https://www.fiercepharma.com/pharma/will-sanofi-and-regenerons-dupixent-be-game-changer-or-just-another-antibody-copd-scrapheap
https://www.globenewswire.com/news-release/2023/03/18/2629819/0/en/Press-Release-Dupixent-dupilumab-late-breaking-data-at-AAD-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis.html
https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670
https://www.globenewswire.com/news-release/2023/03/07/2621674/0/en/Dupixent-dupilumab-Application-for-Treatment-of-Chronic-Spontaneous-Urticaria-CSU-in-Adults-and-Adolescents-Aged-12-Years-and-Older-Accepted-for-FDA-Review.html
https://www.globenewswire.com/news-release/2023/02/03/2601072/0/en/Press-Release-Strong-sales-performance-and-double-digit-EPS-growth-marking-the-achievement-of-the-2022-profitability-milestone.html
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-forecasts-fx-adjusted-profit-growth-dupixent-prescriptions-2023-02-03/
https://www.sanofi.com/en/media-room/press-releases/2023/2023-01-30-06-00-00-2597236
https://www.globenewswire.com/news-release/2023/01/27/2596596/0/en/Dupixent-dupilumab-Recommended-for-Expanded-EU-Approval-by-the-CHMP-to-Treat-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html
Market Place
Share 
